Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207429 | 0.84 | CA2 (0.38) | GABRA1GABRB2CA2 | |
| SCHEMBL29213578 | 0.81 | CA2 (0.36) | GABRA1GABRB2CA2 | |
| SCHEMBL1067884 | 0.78 | RAPGEF4 (0.31) | — | |
| SCHEMBL28517757 | 0.78 | NPC1 (0.30) | — | |
| SCHEMBL7953267 | 0.77 | CA2 (0.33) | CA2 | |
| SCHEMBL19280 | 0.74 | — | — | |
| SCHEMBL2696387 | 0.73 | CA2 (0.31) | CA2 | |
| SCHEMBL11504024 | 0.73 | CA2 (0.31) | CA2 | |
| SCHEMBL4633271 | 0.70 | KDM4E (0.31) | — | |
| SCHEMBL1777222 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 381 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958042-B2 | Reactions of olefin derivatives in the presence of metathesis catalysts | UMICORE AG & CO. KG (DE) | 2024-04-16 | — | — | US | claimed |
| EP-4194092-A1 | SYNTHESIS AND CHARACTERIZATION OF METATHESIS CATALYSTS | Umicore AG & Co. KG (DE) | 2023-06-14 | — | — | EP | claimed |
| EP-3503999-B1 | SYNTHESIS AND CHARACTERIZATION OF METATHESIS CATALYSTS | UMICORE AG & CO KG (DE) | 2022-12-07 | — | — | EP | claimed |
| EP-4028464-A1 | HIGH-VOLTAGE COMPONENTS | LANXESS Deutschland GmbH (DE) | 2022-07-20 | — | — | EP | claimed |
| EP-4028465-A1 | HIGH-VOLTAGE COMPONENTS | LANXESS Deutschland GmbH (DE) | 2022-07-20 | — | — | EP | claimed |
| CN-114364746-A | High-voltage component | 朗盛德国有限责任公司 | 2022-04-15 | — | — | CN | claimed |
| CN-114364728-A | High-voltage component | 朗盛德国有限责任公司 | 2022-04-15 | — | — | CN | claimed |
| CN-109641198-B | Synthesis and characterization of metathesis catalysts | 优美科股份公司及两合公司 | 2022-04-12 | — | — | CN | claimed |
| US-20220055025-A1 | REACTIONS OF OLEFIN DERIVATIVES IN THE PRESENCE OF METHATHESIS CATALYSTS | UMICORE AG & CO. KG (DE) | 2022-02-24 | — | — | US | claimed |
| EP-3938442-A1 | HIGH VOLTAGE COMPONENTS | LANXESS Deutschland GmbH (DE) | 2022-01-19 | — | — | EP | claimed |
| CN-104592425-B | A kind of cycloheptatriene base rare-earth metal catalyst, preparation method and application | 北京理工大学 | 2017-03-08 | — | — | CN | claimed |
| EP-2043633-B1 | THIADIAZOLIDINONE DERIVATIVES FOR TREATING CANCER | UNIV ROCHESTER (US) | 2016-07-06 | — | — | EP | claimed |
| US-7642324-B2 | Methods of using heterocycle-amine ligands, compositions, complexes, and catalysts | SYMYX SOLUTIONS, INC. (US) | 2010-01-05 | — | — | US | claimed |
| US-7642216-B2 | Methods of using heterocycle-amine ligands, compositions, complexes, and catalysts | SYMYX SOLUTIONS, INC. (US) | 2010-01-05 | — | — | US | claimed |
| US-20090143222-A1 | METHODS OF USING HETEROCYCLE-AMINE LIGANDS, COMPOSITIONS, COMPLEXES, AND CATALYSTS | SYMYX TECHNOLOGIES, INC. (US) | 2009-06-04 | — | — | US | claimed |
| US-20090131619-A1 | METHODS OF USING HETEROCYCLE-AMINE LIGANDS, COMPOSITIONS, COMPLEXES, AND CATALYSTS | SYMYX TECHNOLOGIES, INC. (US) | 2009-05-21 | — | — | US | claimed |
| EP-0463488-B2 | O-Benzyl oxime ethers and fungicides containing them | BASF AG (DE) | 2004-04-21 | — | — | EP | claimed |
| US-5017633-A | Oxidation resistance | SANDOZ LTD. (CH) | 1991-05-21 | — | — | US | claimed |
| US-4772717-A | Novel process for the preparation of biotin | PFIZER INC. (US) | 1988-09-20 | — | — | US | claimed |
| US-3969407-A | Substituted carbamoyl sulfines and their manufacture | MONSANTO COMPANY (US) | 1976-07-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055025-A1 | REACTIONS OF OLEFIN DERIVATIVES IN THE PRESENCE OF METHATHESIS CATALYSTS | MDK, MTR, MUSK | GABRA1 2147/4885GABRB2 2645/4885CA2 4594/4885 |
| US-11958042-B2 | Reactions of olefin derivatives in the presence of metathesis catalysts | SYMPK, MDK, HCK | GABRA1 4458/4885GABRB2 4509/4885CA2 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.